Peritoneal Dialysis Solution Biocompatibility: Inhibitory Mechanisms and Recent Studies with Bicarbonate-Buffered Solutions

Davies S.J. , Bryan J. , Phillips L. , Russell G.I. Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis Nephrol Dial Transplant 1996; 11: 498–506.

Topley N. , Davenport A. , Li F-K , Fear H. , Williams J.D. Activation of inflammation and leukocyte recruitment into the peritoneal cavity. Kidney Int 1996; 50: S17–21.

Topley N. , Williams J.D. The role of the peritoneal membrane in the control of inflammation in the peritoneal cavity. Kidney Int 1994; 46: S71–8.

Beavis M.J. , Williams J.D. , Hoppe J. , Topley N. Human peritoneal fibroblast proliferation in 3-dimensional culture: modulation by cytokines, growth factors and peritoneal dialysis effluent. Kidney Int 1997; 51: 205–15.

Jörres A. , Ludat K. , Lang J. Establishment and functional characterisation of human peritoneal fibroblasts in culture: regulation of interleukin-6 production by pro-inflammatory cytokines. J Am Soc Nephrol 1996; 7: 2192–201.

Pollock C.A. , Ibels L.S. , Eckstein R.P. Peritoneal morphology on maintenance dialysis. Am J Nephrol 1989; 9: 198–204.

Slingeneyer A. , Canaud B. , Mion C. Permanent loss of ultrafiltration capacity of the peritoneum in long term peritoneal dialysis: an epidemiological study. Nephron 1983; 33: 133–8.

Duwe A.K. , Vas S.I. , Weatherhead J.W. Effects of the composition of peritoneal dialysis fluid on chemiluminescence, phagocytosis and bactericidal activity in vitro. Infect Immun 1981; 33: 130–5.

Jörres A. , Gahl G.M. , Frei U. Peritoneal dialysis fluid biocompatibility: does it really matter? Kidney Int 1994; 46: S79–86.

Gotloib L. , Wajsbrot V. , Shostak A. , Kushnier R. Population analysis of mesothelium in situ and in vivo exposed to bicarbonate-buffered peritoneal dialysis fluid. Nephron 1996; 73: 219–27.

Gotloib L. , Wajsbrot V. , Shostak A. , Kushnier R. Acute and long-term changes observed in imprints of mouse mesothelium exposed to glucose-enriched, lactated, buffered dialysis solutions. Nephron 1995; 70: 466–77.

Gotloib L. , Wajsbrot V. , Shostak A. , Kushnier R. Biocompatibility of dialysis solutions evaluated by histochemical techniques applied to mesothelial cell imprints Perit Dial Int 1993; 13: 201–7.

Haag-Weber M. , Hörl W.H. Impact of continuous ambulatory peritoneal dialysis solutions and clearance of macromolecules on polymorphonuclear neutrophils. Perit Dial Int 1994; 14: S33–8.

Holmes C.J. Biocompatibility of peritoneal dialysis solutions. Perit Dial Int 1993; 13: 88–94.

Jörres A. , Topley N. , Witowski J. , Liberek T. , Gahl G.M. Impact of peritoneal dialysis solutions on peritoneal immune defence. Perit Dial Int 1993; 13: S291–4.

Jörres A. , Topley N. , Gahl G.M. Biocompatibility of peritoneal dialysis fluids [Editovial]. Int J Art Organs 1992; 15: 79–83.

Topley N. Bio-compatibility in peritoneal dialysis. French PD Club. Nimes, 1994.

Wieslander A.P. , Nordin M.K. , Kjellstrand P.T.T. , Boberg U.C. Toxicity of peritoneal dialysis fluids on cultured fibroblasts, L-929. Kidney Int 1991; 40: 77–9.

Wieslander A.P. , Nordin M.K. , Martinson E. , Kjellstrand P.T.T. , Boberg U.C. Heat sterilised PD-fluids impair growth and inflammatory responses of cultured cell lines and human leukocytes. Clin Nephrol 1993; 39: 343–8.

Liberek T. , Topley N. , Jorres A. Peritoneal dialysis fluid inhibition of polymorphonuclear leucocyte respiratory burst activation is related to the lowering of intra-cellular pH. Nephron 1993; 65: 260–5.

Topley N. , Alobaidi H.M. , Davies M. The effect of dialysate on peritoneal phagocyte oxidative metabolism. Kidney Int 1988; 34: 404–11.

Douvdevani A. , Rapoport J. , Konforty A. Intracellular acidification mediates the inhibitory effect of peritoneal dialysate on peritoneal macrophages. JAm Soc Nephrol 1995; 6: 207–13.

Dobbie J. , Lloyd J. , Gall C. Categorization of ultrastructural changes in peritoneal mesothelium, stroma and blood vessels in uremia and CAPD patients. In: Khanna R. , Nolph K.D. , Prowant B.F. , Twardowski Z.J. , Oreopoulos D.G. , eds. Advances in peritoneal dialysis. Toronto: Peritoneal Dialysis Bulletin, 1990.

Witowski J. , Williams J.D. , Topley N. D-Glucose induces transforming growth factor-bl (TGF-β) mRNA expression and secretion in human peritoneal mesothelial cells (HPMC): effect of hyperosmolality. Perit Dial Int 1997; 17(Suppl 1): S10

Wahl S.M. Fibrosis: bacterial cell wall induced hepatic granulomas. In: Gallin J.I. , Goldstein I.M. , and Snyderman R. , eds. Basic principles and clinical correlates. New York: Raven Press, 1988; 841–59.

Wieslander A.P. , Andren A.H.G. , Nilsson-Thorell C. Are aldehydes in heat sterilised peritoneal dialysis fluids toxic in vitro? Perit Dial Int 1995; 15: 348–52.

Wieslander A. Cytotoxicity of glucose degradation products in PD fluids (PhD thesis). Lund: University of Lund, Sweden, 1995.

Wieslander A. , Andren A.H.G. , Nilsson-Thorell C. Are aldehydes in heat-sterilised peritoneal dialysis fluids toxic in vitro? Perit Dial Int 1995; 15: 348–52.

Nilsson-Thorell C.B. , Muscalu N. , Andren A.H.G. , Kjellstrand P.T.T. , Wieslander A.P. Heat sterilisation of peritoneal dialysis gives rise to aldehydes. Perit Dial Int 1993; 13: 208–13.

Liberek T. , Topley N. , Jorres A. Peritoneal dialysis fluid inhibition of phagocyte function: effects of osmolality and glucose concentration. J Am Soc Nephrol 1993; 3: 1508–15.

Koobs D.H. Phosphate mediation of the Crabtree and Pasteur effects. Science 1972; 178: 127–33.

Saner A. , Blacker F. , Malaisse W. Crabtree effect in tumoral pancreatic islet cells. J Biol Chem 1988; 263: 1904–9.

Tilton R.G. , Baier L.D. , Harlow J.E. Diabetes-induced glomerular dysfunction: links to a more reduced cytosolic ratio of NADH/NAD+. Kidney Int 1992; 41: 778–88.

Witowski J. , Topley N. , Jorres A. Effect of lactate buffered peritoneal dialysis fluids on human peritoneal mesothelial cell interleukin-6 and prostaglandin synthesis. Kidney Int 1995; 47: 282–93.

Jorres A. , Gahl G.M. , Topley N. In vitro biocompatibility of alternative CAPD fluids; comparison of bicarbonate buffered and glucose polymer based solutions. Nephrol Dial Transplant 1994; 9: 785–90.

van Bronswijk H. , Verbrugh H.A. , Bos H.J. Cytotoxic effects of commercial continuous ambulatory peritoneal dialysis (CAPD) fluids and of bacterial exoproducts on human mesothelial cells in vitro. Perit Dial Int 1989; 9: 197–202.

Alobaidi H.M. , Coles G.A. , Davies M. , Lloyd D. Host defence in continuous ambulatory peritoneal dialysis: The effect of the dialysate on phagocyte function. Nephrol Dial Transplant 1986; 1: 16–21.

Ahmed M.I. , Rawal P.A. , Patel N.M. In vitro buffering capacity of residual peritoneal dialysis fluid: implications for peritoneal dialysis therapy ArtifOrgans 1992; 16: 416–8.

de Fijter C.W.H. , Verbrugh H.A. , Oe L.P. Peritoneal defence in continuous ambulatory versus continuous cyclic peritoneal dialysis. Kidney Int 1992; 42: 947–50.

de Fijter C.W.H. , Verbrugh H.A. , Oe L.P. Biocompatibility of a glucose polymer-containing peritoneal dialysis fluid. Am J Kidney Dis 1993; 4: 411–8.

de Fijter C.W.H. , Verbrugh H.A. , Peters ED J. In vivo exposure to the currently available peritoneal dialysis fluids decreases the function of peritoneal macrophages in CAPD. Clin Nephrol 1993; 39: 75–80.

de Fijter C.W.H. , Verbrugh H.A. , Oe P.L. Antibacterial peritoneal defence in automated peritoneal dialysis: advantages of tidal over continuous cyclic peritoneal dialysis? Nephrol Dial Transplant 1994; 9: 156–62.

de Fijter C.W.H. , Oe L.P. , Heezius ECJM , Donker A.J.M. , Verbrugh H.A. Low-calcium peritoneal dialysis fluid should not impact peritonitis rates in continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1996; 27: 409–15.

Veech R.L. The untoward effects of the anions of dialysis fluids. Kidney Int 1988; 34: 587–97.

Feriani M. , Biasioli S. , Borin D. Bicarbonate solutions for peritoneal dialysis: a reality. Int J Artif Organs 1985; 8: 57–8.

Dobos G.J. , Böhler J. , Kuhlmann J. Bicarbonate-based dialysis solutions preserves granulocyte functions. Perit Dial Int 1994; 14: 366–70.

Fischer H-P , Schenk U. , Kiefer T. In vitro effects of bicarbonate versus lactate-buffered continuous ambulatory peritoneal dialysis fluids on peritoneal macrophage function. Am J Kidney Dis 1995; 26: 924–33.

Topley N. , Kaur D. , Petersen M.M. Improved human peritoneal mesothelial cell (HPMC) viability and function in bicarbonate-buffered peritoneal dialysis fluids. Nephrol Dial Transplant 1994; 9: 1026.

Topley N. , Kaur D. , Petersen M.M. Bio-compatibility of bicarbonate-buffered peritoneal dialysis fluids: influence on mesothelial cell and neutrophil functioni. Kidney Int 1996; 49: 1447–56.

Topley N. , Kaur D. , Petersen M.M. In vitro effects of bicarbonate and bicarbonate-lactate buffered peritoneal dialysis solutions on mesothelial cell and neutrophil function. J Am Soc Nephrol 1996; 7: 218–24.

Yatzidis H. A new stable bicarbonate dialysis solution for peritoneal dialysis: preliminary report. Perit Dial Int 1991; 11: 224–7.

Yatzidis H. Enhanced ultrafiltration in rabbits with bicarbonate glycylglycine peritoneal dialysis solution. Perit Dial Int 1993; 13: 302–6.

Mackenzie R. , Williams J.D. , Moseley A. In vivo exposure to bicarbonate/lactate (TBL) and bicarbonate (TB) buffered dialysis fluids (PDF) improves peritoneal macrophage (PM) function. J Am Soc Nephrol 1996; 7: 1342.